Infigratinib in Upper Tract Urothelial Carcinoma Versus Urothelial Carcinoma of the Bladder and Its Association With Comprehensive Genomic Profiling and/or Cell-Free DNA Results

BACKGROUND: Infigratinib (BGJ398) is a potent and selective fibroblast grown factor receptor 1 to 3 (FGFR1–3) inhibitor with significant activity in patients with advanced or metastatic urothelial carcinoma bearing FGFR3 alterations. Given the distinct biologic characteristics of upper tract urothel...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer
Main Authors: Pal, Sumanta K., Bajorin, Dean, Dizman, Nazli, Hoffman-Censits, Jean, Quinn, David I., Petrylak, Daniel P., Galsky, Matthew D., Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard A., Soifer, Harris S., Li, Gary, Wang, Hao, Dambkowski, Carl L., Moran, Susan, Daneshmand, Siamak, Rosenberg, Jonathan E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7515773/
https://ncbi.nlm.nih.gov/pubmed/32208524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32806
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados